タグシクス・バイオ株式会社(東京都目黒区駒場、代表取締役社長 古関千寿子)は、東京大学協創プラットフォーム開発株式会社(東京都文京区本郷、代表取締役社長 大泉克彦)、などを引受先とする総額約2億円の第三者割当増資を実施しましたので、お知らせいたします。




February 19 2020: TAGCyx and GC Pharma (formerly known as Green Cross Corporation) has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004.

TAGCyx has signed Joint Research and Development Agreement with GC Pharma (KRX: 006280) in relation to pursuing various pre-clinical studies of TAGX-0004, an anti-human vWF DNA aptamer containing proprietary artificial nucleotide.
TAGCyx has invented artificial nucleic acid base pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”, that is regarded to be an alternative to antibody therapeutics.

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century.

TAGX-0004 is an innovative DNA aptamer therapeutics developed by TAGCyx aiming to treat thrombotic disorders such as brain and cardiac infarction, and currently under development for rare disease called acquired thrombotic thrombocytopenic purpura (aTTP). TAGCyx has accumulated many pharmacological data to date in collaboration with a Japanese leading scientist in the field, Professor Masanori Matsumoto, Nara Medical University.

Dr. Chizuko Koseki, Chief Executive Officer of TAGCyx added “Together with GC Pharma, we believe our aptamer will be a key therapeutic option for the patient of aTTP, and eventually for other thrombotic diseases. GC Pharma’s deep insight will realize TAGCyx’ mission to provide an effective treatment to various challenging diseases”.

Under the agreement, GC Pharma will fund the development cost for pre-agreed pre-clinical studies, and TAGCyx will conduct the studies with CROs. Under the confidentiality of the agreement, further detail of the research is not disclosed.


当社は、株式会社ヘリオス(代表執行役社長CEO 鍵本 忠尚、本社:東京都港区、東証マザーズ、以下「ヘリオス」といいます。)と、当社独自のXenoligo®技術を用いたアプタマーの再生医薬品分野における利用について共同研究を実施しておりますが、この度、予め設定したマイルストンを達成し、マイルストンペイメントを受領いたしましたので、お知らせいたします。


 ・ ”標的タンパク質に結合する核酸断片”が、欧州、韓国、中国で成立
 ・ ”DNAアプタマーの安定化法“が、日本と米国で成立
 ・ ” vWFに結合するDNAアプタマー“がシンガポールで成立